Industry News
Patrys doses second group in myeloma trial
Patrys (ASX:PAB) has completed initial treatment for half of the 12 multiple myeloma patients to be involved in a clinical trial of anticancer antibody PAT-SM6. [ + ]
Metagenomics used to identify organisms in serious disease outbreaks
Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli (STEC) that caused over 50 deaths in Germany. They used an approach known as metagenomics, which bypasses the need for growing bacteria in the lab. [ + ]
Good fellows and great science
The Australian Synchrotron has announced the establishment of the Australian Synchrotron Fellows Program, available to outstanding individuals whose passion for science matches that of the AS’s staff and who will be rewarded with access to Australia’s premier scientific and innovation support facility. [ + ]
pSivida launches social media push
pSivida (ASX:PVA) has launched channels on each of the four major social networks to provide more outlets to communicate key information to investors. [ + ]
Pharmaxis names Brazil distributor for Bronchitol
Pharmaxis (ASX:PXS) has tapped United Medical as its exclusive distribution partner and sales rep for cystic fibrosis treatment Bronchitol in Brazil. [ + ]
On-the-spot test to breed success
UK diagnostics development company AgPlus Diagnostics is to collaborate with New Zealand-based BioTest Diagnostics in the development of a rapid and convenient test for canine progesterone that will be used to pinpoint the narrow window for artificial insemination in canine breeding programs. [ + ]
Are people really staring at you?
People often think that other people are staring at them even when they aren’t, vision scientists have found. [ + ]
What happens when a chemical bond is broken?
That question was recently answered with the help of a so-called free electron X-ray laser, which makes it possible to follow in real time how bindings in a molecule are changed and broken. The study, published in Science, found, among other things, evidence of a much-discussed intermediate state before molecules bind to or leave a metal surface. The possibility of monitoring at the molecular level how the electron structure changes in a chemical reaction creates entirely new opportunities for investigating and understanding key chemical processes in detail. [ + ]
Four more surgeons cleared to use CardioCel
Allied Healthcare (ASX:AHZ) says five surgeons have now received early approval to use heart patch CardioCel under the TGA’s Authorized Prescriber Scheme. [ + ]
Clinuvel’s EU application for Scenesse delayed
The EMA has allocated more time to review Clinuvel’s (ASX:CUV) application for approval of Scenesse as an EPP treatment. [ + ]
Australia’s first Biohackathon
A Biohackathon will open up scientific problem solving to the public next week in Sydney. [ + ]
Novogen reaches cancer drug milestone
Novogen (ASX:NRT) has revealed that one enantiomer of cancer drug candidate CS-6 appears many times more active against brain cancer than the reverse form. [ + ]
Company evaluating pSivida eye drug insert tech
A company is evaluating using pSivida’s (ASX:PVA) eye drug delivery technologies Durasert and Tethadur for its own ophthalmic drug products. [ + ]
Applikon to buy HaloteC’s biotech portfolio
Applikon Biotechnology will buy part of the product portfolio of HaloteC Instruments and integrate the instruments and software tech into its bioreactor software offerings. [ + ]
Record funding for cancer research in the west
The Cancer Council of Western Australia recently allocated $2.8 million in annual funding for research in Western Australia. [ + ]
